Cargando…
Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues
A novel series of 5-arylcarbamoyl- and 5-arylmethyl-2-methylisoxazolidin-3-yl-3-phosphonates have been synthesized via cycloaddition of N-methyl-C-(diethoxyphosphoryl)nitrone with N-substituted naphthalimide acrylamides and N-allylnaphthalimides. All cis- and trans-isoxazolidine phosphonates obtaine...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126999/ https://www.ncbi.nlm.nih.gov/pubmed/26001344 http://dx.doi.org/10.1016/j.bmc.2015.04.079 |
_version_ | 1783516266833641472 |
---|---|
author | Kokosza, Kamil Andrei, Graciela Schols, Dominique Snoeck, Robert Piotrowska, Dorota G. |
author_facet | Kokosza, Kamil Andrei, Graciela Schols, Dominique Snoeck, Robert Piotrowska, Dorota G. |
author_sort | Kokosza, Kamil |
collection | PubMed |
description | A novel series of 5-arylcarbamoyl- and 5-arylmethyl-2-methylisoxazolidin-3-yl-3-phosphonates have been synthesized via cycloaddition of N-methyl-C-(diethoxyphosphoryl)nitrone with N-substituted naphthalimide acrylamides and N-allylnaphthalimides. All cis- and trans-isoxazolidine phosphonates obtained herein were assessed for antiviral activity against a broad range of DNA and RNA viruses. Isoxazolidines trans-9d and trans-9f exhibited the highest activity (EC(50) = 8.9 μM) toward cytomegalovirus. Compounds cis- and trans-9d as well as cis- and trans-9f were found potent against HSV and Vaccinia viruses (EC(50) in the 45–58 μM range), whereas isoxazolidines 10a and 10d suppressed replication of Coxsackie B4 and Punta Toro viruses (EC(50) in the 45–73 μM range). Antiproliferative evaluation of all obtained isoxazolidines revealed the promising activity of cis-9b, cis-9d, trans-9d, cis-9e, trans-9e, cis-9f and trans-9f toward tested cancer cell lines with IC(50) in the 1.1–19 μM range. |
format | Online Article Text |
id | pubmed-7126999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71269992020-04-08 Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues Kokosza, Kamil Andrei, Graciela Schols, Dominique Snoeck, Robert Piotrowska, Dorota G. Bioorg Med Chem Article A novel series of 5-arylcarbamoyl- and 5-arylmethyl-2-methylisoxazolidin-3-yl-3-phosphonates have been synthesized via cycloaddition of N-methyl-C-(diethoxyphosphoryl)nitrone with N-substituted naphthalimide acrylamides and N-allylnaphthalimides. All cis- and trans-isoxazolidine phosphonates obtained herein were assessed for antiviral activity against a broad range of DNA and RNA viruses. Isoxazolidines trans-9d and trans-9f exhibited the highest activity (EC(50) = 8.9 μM) toward cytomegalovirus. Compounds cis- and trans-9d as well as cis- and trans-9f were found potent against HSV and Vaccinia viruses (EC(50) in the 45–58 μM range), whereas isoxazolidines 10a and 10d suppressed replication of Coxsackie B4 and Punta Toro viruses (EC(50) in the 45–73 μM range). Antiproliferative evaluation of all obtained isoxazolidines revealed the promising activity of cis-9b, cis-9d, trans-9d, cis-9e, trans-9e, cis-9f and trans-9f toward tested cancer cell lines with IC(50) in the 1.1–19 μM range. Elsevier Ltd. 2015-07-01 2015-05-06 /pmc/articles/PMC7126999/ /pubmed/26001344 http://dx.doi.org/10.1016/j.bmc.2015.04.079 Text en Copyright © 2015 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Kokosza, Kamil Andrei, Graciela Schols, Dominique Snoeck, Robert Piotrowska, Dorota G. Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues |
title | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues |
title_full | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues |
title_fullStr | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues |
title_full_unstemmed | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues |
title_short | Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues |
title_sort | design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126999/ https://www.ncbi.nlm.nih.gov/pubmed/26001344 http://dx.doi.org/10.1016/j.bmc.2015.04.079 |
work_keys_str_mv | AT kokoszakamil designantiviralandcytostaticpropertiesofisoxazolidinecontainingamonafideanalogues AT andreigraciela designantiviralandcytostaticpropertiesofisoxazolidinecontainingamonafideanalogues AT scholsdominique designantiviralandcytostaticpropertiesofisoxazolidinecontainingamonafideanalogues AT snoeckrobert designantiviralandcytostaticpropertiesofisoxazolidinecontainingamonafideanalogues AT piotrowskadorotag designantiviralandcytostaticpropertiesofisoxazolidinecontainingamonafideanalogues |